Detail

Professor Lichtenberg teaches the core course Global Economic Environment. His research examines how the introduction of new technology arising from research and development affects the productivity of companies, industries and nations. Recently, he has studied the impact of new drugs on hospitalization rates, the effect of computers on productivity in business and government organizations and the consequences of takeovers and LBOs for efficiency and employment. A research associate of the National Bureau of Economic Research, Lichtenberg has received numerous research fellowships and grants, served as a consultant to a variety of private and public organizations and testified before Congress.

• Winner of the 1998 Schumpeter Prize
  For the paper "Pharmaceutical innovation as a process of creative destruction"
• 2003 Milken Institute Award for Distinguished Economic Research
  For the paper "Pharmaceutical knowledge-capital accumulation and longevity"
• 2010 Garfield Economic Impact Award
  For the publication "The Effect of New Cancer Drug Approvals on the Life Expectancy of American Cancer Patients, 1978 - 2004

• Spring 2013
  Economics of Health Care & Pharmaceuticals (MBA)
  
• Fall 2012
  Economics of Healthcare & Pharmaceuticals (EMBA)
  Managerial Economics (1.5 cr) (EMBA)
  
• Spring 2011
  Economics of Health Care & Pharmaceuticals (MBA)
  
• Fall 2011
  Managerial Economics (1.5 cr) (EMBA)
  
• Spring 2010
  Economics of Health Care & Pharmaceuticals (MBA)
  
• Spring 2009
  Economics of Health Care & Pharmaceuticals (MBA)
  Economics of Healthcare & Pharmaceuticals (EMBA)
  
• Fall 2009
  Global Economic Environment I & II (EMBA)
  Managerial Economics (MBA)
  

Pharmaceutical Knowledge-Capital Accumulation and Longevity In Measuring Capital in the New Economy (2005)
Author(s): Frank Lichtenberg

The contribution of pharmaceutical innovation to longevity growth in Germany and France, 2001–2007 In PharmacoEconomics (2012)
Author(s): Frank Lichtenberg

Has Pharmaceutical Innovation Reduced Social Security Disability Growth? In International Journal of the Economics of Business (2011)
Author(s): Frank Lichtenberg

Despite steep costs, payments for new cancer drugs make economic sense In Nature Medicine (2011)
Author(s): Frank Lichtenberg

The quality of medical care, behavioral risk factors, and longevity growth In International Journal of Health Care Finance and Economics (2011)
Author(s): Frank Lichtenberg

What Are the Respective Roles of the Public and Private Sectors in Pharmaceutical Innovation? In Health Affairs (2011)
Author(s): Frank Lichtenberg, Bhaven Sampat

Are Increasing 5-Year Survival Rates Evidence of Success Against Cancer? A Reexamination Using Data from the U.S. and Australia In Forum for Health Economics & Policy (2010)
Author(s): Frank Lichtenberg

Pharmaceutical innovation and mortality in the United States, 1960–2000. A commentary on Schnittker and Karandinos In Social Science and Medicine (2010)
Author(s): Frank Lichtenberg

Pharmaceutical Price Discrimination and Social Welfare In Capitalism and Society (2010)
Author(s): Frank Lichtenberg

The effect of drug vintage on survival: Micro evidence from Puerto Rico's Medicaid program In Advances in health economics and health services research (2010)
Author(s): Frank Lichtenberg

Availability of New Drugs and Americans' Ability to Work In Journal of Occupational and Environmental Medicine (2005)
Author(s): Frank Lichtenberg

The Impact of New Drug Launches on Longevity: Evidence from Longitudinal, Disease-Level Data from 52 Countries, 1982-2001 In International Journal of Health Care Finance and Economics (2005)
Author(s): Frank Lichtenberg

The Effects of Medicare on Health Care Utilization and Outcomes In Frontiers in Health Policy Research (2002)
Author(s): Frank Lichtenberg

Do (More and Better) Drugs Keep People Out of Hospitals? In American Economic Review (1996)
Author(s): Frank Lichtenberg

The Private R and D Investment Response to Federal Design and Technical Competitions In American Economic Review (1988)
Author(s): Frank Lichtenberg

The Comparative Advantage of Educated Workers in Implementing New Technology In Review of Economics and Statistics (1987)
Author(s): Ann Bartel, Frank Lichtenberg

Corporate Takeovers and Productivity (1992)
Author(s): Frank Lichtenberg

The Impact of New (Orphan) Drug Approvals on Premature Mortality from Rare Diseases in the U.S. and France, 1999–2007 Working Paper (2011)
Author(s): Frank Lichtenberg

Has medical innovation reduced cancer mortality? Working Paper No. 15880 (2010)
Author(s): Frank Lichtenberg

Is Home Health Care a Substitute for Hospital Care? Working paper (2010)
Author(s): Frank Lichtenberg

The impact of medical knowledge accumulation and diffusion on health: Evidence from Medline and other N.I.H. data Working paper (2010)
Author(s): Frank Lichtenberg

The Quality of Medical Care, Behavioral Risk Factors, and Longevity Growth NBER Working Papers, Working Paper 15068 (2009)
Author(s): Frank Lichtenberg

Benefits and Costs of Newer Drugs: An Update Working paper (2005)
Author(s): Frank Lichtenberg

Pharmaceutical-Embodied Technical Progress, Longevity, and Quality of Life: Drugs as 'Equipment for Your Health' Working paper (2005)
Author(s): Frank Lichtenberg, Suchin Virabhak

Sources of U.S. Longevity Increase, 1960-1997 Working paper (2005)
Author(s): Frank Lichtenberg

The Dual Effects of Intellectual Property Regulations: Within- and Between-Patent Competition in the U.S. Pharmaceuticals Industry Working paper (2005)
Author(s): Frank Lichtenberg

The Effect of Changes in Drug Utilization on Labor Supply and Per Capita Output Working paper (2005)
Author(s): Frank Lichtenberg

The Effect of Education on Medical Technology Adoption: Are the More Educated More Likely to Use New Drugs? Working paper (2005)
Author(s): Adriana Lleras-Muney, Frank Lichtenberg

The Expanding Pharmaceutical Arsenal in the War on Cancer NBR Working Paper 10328 (2005)
Author(s): Frank Lichtenberg

The Impact of New Drug Launches on Longevity: From 52 Countries, 1982-2001 Working paper (2005)
Author(s): Frank Lichtenberg

The Effect of New Drugs on Mortality from Rare Diseases and HIV NBER Working Paper 8677 (2002)
Author(s): Frank Lichtenberg

The Benefits and Costs of Newer Drugs: Evidence from the 1996 Medical Expenditure Panel Survey NBER Working Paper 8147 (2001)
Author(s): Frank Lichtenberg

Pharmaceutical Innovation, Mortality Reduction, and Economic Growth NBER Working Paper W6569 (1998)
Author(s): Frank Lichtenberg

The Allocation of Publicly-Funded Biomedical Research NBER Working Paper 6601 (1998)
Author(s): Frank Lichtenberg

The Effect of Pharmaceutical Utilization and Innovation on Hospitalization and Mortality NBER Working Paper No. W5418 (1996)
Author(s): Frank Lichtenberg